Who makes CP-778,875?

CP-778,875 is developed by Pfizer.

Last reviewed 2026-04-23 · How we verify

CP-778,875

Pfizer · Phase 2 active Small molecule

At a glance

Generic name	CP-778,875
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CP-778,875 CI brief — competitive landscape report
CP-778,875 updates RSS · CI watch RSS
Pfizer portfolio CI